Sun Pharmaceutical Industries Limited – Product Pipeline Review – H2 2011

Date: November 1, 2011
Pages: 120
Price:
US$ 500.00 US$ 450.00
Offer valid until December 31, 2014!
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: S8D5A79E7AFEN
Leaflet:

Download PDF Leaflet

Sun Pharmaceutical Industries Limited – Product Pipeline Review – H2 2011

Summary

Global Market Direct’s pharmaceuticals report, “Sun Pharmaceutical Industries Limited - Product Pipeline Review - H2 2011” provides data on the Sun Pharmaceutical Industries Limited’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Sun Pharmaceutical Industries Limited’s corporate website, SEC filings, investor presentations and featured press releases, both from Sun Pharmaceutical Industries Limited and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope
  • Sun Pharmaceutical Industries Limited - Brief Sun Pharmaceutical Industries Limited overview including business description, key information and facts, and its locations and subsidiaries.
  • Review of current pipeline of Sun Pharmaceutical Industries Limited human therapeutic division.
  • Overview of pipeline therapeutics across various therapy areas.
  • Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
  • Product profiles for late stage and clinical stage products of Sun Pharmaceutical Industries Limited with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
  • Recent updates of the Sun Pharmaceutical Industries Limited’s pipeline in the last quarter.
  • Key discontinued and dormant projects.
  • Latest news and deals relating to the products.

Reasons to buy
  • Evaluate Sun Pharmaceutical Industries Limited’s strategic position with total access to detailed information on its product pipeline.
  • Assess the growth potential of Sun Pharmaceutical Industries Limited in its therapy areas of focus.
  • Identify new drug targets and therapeutic classes in the Sun Pharmaceutical Industries Limited’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
  • Exploit collaboration and partnership opportunities with Sun Pharmaceutical Industries Limited.
  • Avoid Intellectual Property Rights related issues.
  • Explore the dormant and discontinued projects of Sun Pharmaceutical Industries Limited and identify potential opportunities in those areas.
Sun Pharmaceutical Industries Limited Snapshot
Sun Pharmaceutical Industries Limited Overview
Key Information
Key Facts
Sun Pharmaceutical Industries Limited – Research and Development Overview
Key Therapeutic Areas
Sun Pharmaceutical Industries Limited – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Sun Pharmaceutical Industries Limited – Pipeline Products Glance
Sun Pharmaceutical Industries Limited – Late Stage Pipeline
Phase III Products/Combination Treatment Modalities
Sun Pharmaceutical Industries Limited Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
Sun Pharmaceutical Industries Limited–Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
Sun Pharmaceutical Industries Limited – Drug Profiles
Baclofen GRS
  Product Description
  Mechanism of Action
  R&D Progress
D-9998
  Product Description
  Mechanism of Action
  R&D Progress
Latanoprost
  Product Description
  Mechanism of Action
  R&D Progress
Naftopidil
  Product Description
  Mechanism of Action
  R&D Progress
SUN 09
  Product Description
  Mechanism of Action
  R&D Progress
SUN 1334 H
  Product Description
  Mechanism of Action
  R&D Progress
SUN 44
  Product Description
  Mechanism of Action
  R&D Progress
SUN-461
  Product Description
  Mechanism of Action
  R&D Progress
Sun Pharmaceutical Industries Limited – Pipeline Analysis
Sun Pharmaceutical Industries Limited – Pipeline Products by Therapeutic Class
Sun Pharmaceutical Industries Limited - Pipeline Products By Target
Sun Pharmaceutical Industries Limited – Pipeline Products by Route of Administration
Sun Pharmaceutical Industries Limited – Pipeline Products by Molecule Type
Sun Pharmaceutical Industries Limited – Company Statement
Sun Pharmaceutical Industries Limited – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Recent Developments
Oct 31, 2011: Sun Pharmaceutical Industries Announces FDA Approval For Generic Cardizem CD
Aug 31, 2010: Sun Pharma Receives FDA Approval For Generic Strattera Capsules
Mar 31, 2008: Sun Pharma Launches Generic Ethyol In US
Dec 30, 2010: Sun Pharma Receives FDA Tentative Approval For Post Menopausal Osteoporosis Drug
Nov 30, 2010: Sun Pharma Wins FDA Tentative Approval For Generic Aricept
Aug 30, 2007: Sun Pharma Receives FDA Tentative Approval For Generic Razadyne Tablets
Jul 30, 2008: Sun Pharma Receives FDA Approval For Generic Depakote Delayed Release Tablets
Jul 30, 2008: Sun Pharma Receives FDA Approval For Generic Depakote Delayed Release Tablets
Jul 30, 2008: Sun Pharma Receives FDA Approval For Generic Depakote Delayed Release Tablets
Jan 30, 2008: Sun Pharma Launches Generic Protonix Tablets In US
Sep 29, 2010: Sun Pharma Receives FDA Tentative Approval For Generic Crestor
Jul 29, 2011: Sun Pharma Announces FDA Tentative Approval For Generic Plavix Tablets
Sep 28, 2010: Sun Pharma Receives FDA Tentative Approval For Generic Rilutek
Mar 28, 2008: Sun Pharma Receives FDA Approval To Market Generic Topamax Tablets
Nov 27, 2008: Sun Pharma Provides Update On ANDA For Generic Effexor XR
Nov 27, 2008: Sun Pharma Provides Update On ANDA For Generic Effexor XR
Feb 27, 2008: Sun Pharma Obtains FDA Approval To Market Generic Demadex Tablets
Feb 27, 2008: Sun Pharma Wins FDA Approval To Market Generic Demadex Tablets
Aug 25, 2007: Sun Pharma Receives FDA Approval To Market Generic Sinemet CR Tablets
Oct 23, 2007: Sun Pharma Receives FDA Approval To Market Generic Exelon Capsules
Sep 23, 2008: Sun Pharma Receives FDA Approval To Market Generic Paraplatin Injection
Sep 23, 2008: Sun Pharma Wins FDA Approval For Generic Paraplatin For Treatment Of Ovarian Carcinoma
Jun 22, 2010: Sun Pharma announces USFDA approval for generic Optivar
Jun 21, 2011: Sun Pharma Announces FDA Approval For Generic Imitrex Injection
Mar 20, 2010: Aurobindo Pharma Receives Approval For Topiramate Tablets From Health Canada
Aug 19, 2010: Sun Pharma Receives FDA Approval For Generic Venlafaxine Hydrochloride ER Tablets
Jun 19, 2009: Sun Pharma Receives FDA Approval For Generic Accupril Tablets
Mar 19, 2008: Sun Pharma Receives FDA Approval To Market Generic Cerebyx
Nov 18, 2010: Sun Pharma Receives FDA Approval For Generic Clarinex
Nov 18, 2010: Sun Pharma Receives FDA Approval For Generic Tiazac ER Capsules
Aug 18, 2007: Sun Pharma Receives FDA Approval To Market Generic Octreotide Injection
Jun 18, 2010: Sun Pharma Receives FDA Approval For Generic Xanax Tablets
Mar 18, 2010: Sun Pharma announces USFDA approval for generic Prometh syrup
Oct 17, 2007: Caraco Pharmaceutical Laboratories Ltd. to Market Generic Trileptal
Jul 17, 2010: Sun Pharma Receives FDA Approval For Generic Flomax
Jun 17, 2010: Sun Pharma Receives FDA Approval For Generic Keppra Injection
Oct 16, 2007: Sun Pharma Receives “Will-not-sue” Covenant On Generic Effexor XR ANDA
Mar 15, 2008: Sun Pharma Receives FDA Approval To Market Generic Ethyol
Feb 14, 2008: Sun Pharma Gets FDA Tentative Approval For Generic Depakote Delayed Release Tablets
Sep 12, 2008: Sun Pharma Receives FDA Approval For Generic Fosamax Tablets
Sep 11, 2007: Sun Pharma Receives FDA Approval To Market Generic Protonix Tablets
Oct 10, 2007: Sun Pharma Receives FDA Approval To Market Generic Trileptal Tablets
Apr 10, 2010: Sun Pharma Receives FDA Tentative Approval For Generic Namenda Tablets
Apr 08, 2010: Sun Pharma Receives FDA Approval For Generic Wellbutrin SR Extended Release Tablets
Oct 07, 2009: Sun Pharma gets USFDA nod for caffeine citrate oral solution
May 07, 2009: Sun Pharma Receives FDA Approval To Market Generic Roxicodone Tablets
May 07, 2009: Sun Pharma Receives FDA Tentative Approval For Generic Uroxatral Tablets
Jan 07, 2009: Sun Pharma Obtains FDA Approval To Market Generic Sinemet Tablets
Jan 07, 2009: Sun Pharma Receives FDA Approval For Pamidronate Disodium For Injection USP
Jan 07, 2009: Sun Pharma Receives FDA Tentative Approval For Generic Lopid Tablets
Jan 07, 2009: Sun Pharma Receives FDA Tentative Approval For Promethazine Hydrochloride
Jan 07, 2008: Sun Pharma Receives FDA Approvals For Generic Hydocodone Bitartate With Acetaminophen Tablets
May 06, 2010: Sun Pharma Announces FDA Approval For Generic Namenda Tablets
Nov 05, 2008: Sun Pharma Wins FDA Approval To Market Generic Sinemet Tablets
Mar 05, 2008: Sun Pharma Receives FDA Tentative Approval For Generic Gemzar Injection
Mar 05, 2008: Sun Pharma Wins FDA Tentative Approval For Generic Gemzar Injection
Feb 03, 2011: Sun Pharma Announces FDA Approval For Generic Razadyne ER
Jul 02, 2009: Sun Pharma Receives FDA Tentative Approval For Generic Optivar
Jul 02, 2009: Sun Pharmaceutical Industries Ltd announces USFDA tentative approval for generic Optivar
Oct 01, 2010: Sun Pharma Receives FDA Tentative Approval For Generic Stalevo
Sep 01, 2010: Sun Pharma announces USFDA approval for generic Keppra Injection, levetiracetam injection
Jul 01, 2010: Sun Pharma Launches Generic Exelon In US
Financial Deals Landscape
Sun Pharmaceutical Industries Limited, Deals Summary
Sun Pharmaceutical Industries Limited, Pharmaceuticals & Healthcare, Deal Details
Asset Transactions
Sun Pharmaceutical Industries Acquires Bryan Manufacturing Facility From Valeant Pharmaceuticals
Sun Pharmaceutical Industries Acquires Dosage Form Manufacturing Operations From Able Labs
Sun Pharmaceutical Acquires Hungary Manufacturing Operations From Valeant Pharmaceuticals
Sun Pharmaceutical Industries Acquires Bactrim, Ortho-Est And Midrin From Women First HealthCare
Partnerships
MSD In India Enters Into Co-Marketing Agreement With Sun Pharmaceutical
Sun Pharmaceutical Industries Enters Into Joint Venture Agreement With MSD Pharmaceuticals
Caraco Pharmaceutical Extends Co-Marketing Agreement With Sun Pharmaceutical
Taro Pharmaceutical Enters Into An Agreement With Quinnova Pharmaceuticals
Caraco Pharmaceutical Enters Into Co-Marketing Agreement With Sun Pharmaceuticals
Taro Pharmaceutical Enters Into Co-Promotion With NextWave Pharmaceuticals
Caraco Pharmaceutical Laboratories Enters Into Agreement With Sun Pharmaceutical Industries
Caraco Pharmaceutical Laboratories Enters Into Agreement With Sun Pharmaceutical Industries
Taro Pharmaceutical Enters Into Co-Development Agreement With J.B. Chemicals
Taro Pharmaceutical Enters Into Co-Development Agreement With Alkem Laboratories
Sun Pharmaceutical Enters Into Distribution Agreement With Caraco Pharmaceutical For Midrin
Taro Pharmaceuticals Enters Into Co-Marketing Agreement With Agis Industries
Licensing Agreements
Sun Pharmaceutical Enters Into Licensing Agreement With MedImmune
Lundbeck Enters Into Licensing Agreement With Sun Pharmaceuticals
Caraco Pharmaceutical Extends Licensing Agreement With Sun Pharmaceutical
Glenmark Generics Enters Into Licensing Agreement With Taro Pharmaceuticals
Caraco Pharmaceutical Enters Into Licensing Agreement With Sun Pharmaceutical
Foamix Enters Into Licensing Agreement With Taro Pharmaceutical For PerFoam 1%
Taro Pharmaceutical Enters Into Licensing Agreement With Alterna For Kerasal
Taro Pharmaceutical Enters Into Licensing Agreement With Alterna
Debt Offering
Sun Pharmaceutical Industries Completes Private Placement Of 4.61% FCCB For $350 Million
Sun Pharmaceutical Issues Foreign Currency Convertible Bonds Due 2009 For $275 Million
Acquisition
Sun Pharmaceutical To Acquire Remaining 33.7% Stake In Taro Pharmaceuticals For $368 Million
Sun Pharmaceutical Acquires Remaining 24% Stake Of Caraco Pharmaceutical
Sun Pharmaceutical Acquires 11.6% Stake In Taro Pharmaceuticals
Sun Pharmaceutical Acquires Controlling Stake In Taro Pharmaceutical
Sun Pharmaceutical Industries Acquires Chattem Chemicals From Elcat
Sun Pharmaceutical Acquires Able Laboratories
Sun Pharmaceutical Industries Acquires Phlox Pharmaceuticals
Sun Pharmaceutical Industries Acquires Additional 1.87% Stake In Caraco Pharmaceutical Laboratories
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Sun Pharmaceutical Industries Limited – Pipeline by Therapy Area and Indication, H2 2011
Sun Pharmaceutical Industries Limited – Pipeline by Stage of Development, H2 2011
Sun Pharmaceutical Industries Limited – Monotherapy Products in Pipeline, H2 2011
Sun Pharmaceutical Industries Limited – Phase III, H2 2011
Sun Pharmaceutical Industries Limited - Phase II, H2 2011
Sun Pharmaceutical Industries Limited - Phase I, H2 2011
Sun Pharmaceutical Industries Limited - Pipeline By Therapeutic Class, H2 2011
Sun Pharmaceutical Industries Limited - Pipeline By Target, H2 2011
Sun Pharmaceutical Industries Limited – Pipeline By Route of Administration, H2 2011
Sun Pharmaceutical Industries Limited – Pipeline By Molecule Type, H2 2011
Sun Pharmaceutical Industries Limited, Other Locations
Sun Pharmaceutical Industries Limited, Subsidiaries
Sun Pharmaceutical Industries Limited, Deals Summary
Sun Pharmaceutical Industries Acquires Bryan Manufacturing Facility From Valeant Pharmaceuticals
Sun Pharmaceutical Industries Acquires Dosage Form Manufacturing Operations From Able Labs
Sun Pharmaceutical Acquires Hungary Manufacturing Operations From Valeant Pharmaceuticals
Sun Pharmaceutical Industries Acquires Bactrim, Ortho-Est And Midrin From Women First HealthCare
MSD In India Enters Into Co-Marketing Agreement With Sun Pharmaceutical
Sun Pharmaceutical Industries Enters Into Joint Venture Agreement With MSD Pharmaceuticals
Caraco Pharmaceutical Extends Co-Marketing Agreement With Sun Pharmaceutical
Taro Pharmaceutical Enters Into An Agreement With Quinnova Pharmaceuticals
Caraco Pharmaceutical Enters Into Co-Marketing Agreement With Sun Pharmaceuticals
Taro Pharmaceutical Enters Into Co-Promotion With NextWave Pharmaceuticals
Caraco Pharmaceutical Laboratories Enters Into Agreement With Sun Pharmaceutical Industries
Caraco Pharmaceutical Laboratories Enters Into Agreement With Sun Pharmaceutical Industries
Taro Pharmaceutical Enters Into Co-Development Agreement With J.B. Chemicals
Taro Pharmaceutical Enters Into Co-Development Agreement With Alkem Laboratories
Sun Pharmaceutical Enters Into Distribution Agreement With Caraco Pharmaceutical For Midrin
Taro Pharmaceuticals Enters Into Co-Marketing Agreement With Agis Industries
Sun Pharmaceutical Enters Into Licensing Agreement With MedImmune
Lundbeck Enters Into Licensing Agreement With Sun Pharmaceuticals
Caraco Pharmaceutical Extends Licensing Agreement With Sun Pharmaceutical
Glenmark Generics Enters Into Licensing Agreement With Taro Pharmaceuticals
Caraco Pharmaceutical Enters Into Licensing Agreement With Sun Pharmaceutical
Foamix Enters Into Licensing Agreement With Taro Pharmaceutical For PerFoam 1%
Taro Pharmaceutical Enters Into Licensing Agreement With Alterna For Kerasal
Taro Pharmaceutical Enters Into Licensing Agreement With Alterna
Sun Pharmaceutical Industries Completes Private Placement Of 4.61% FCCB For $350 Million
Sun Pharmaceutical Issues Foreign Currency Convertible Bonds Due 2009 For $275 Million
Sun Pharmaceutical To Acquire Remaining 33.7% Stake In Taro Pharmaceuticals For $368 Million
Sun Pharmaceutical Acquires Remaining 24% Stake Of Caraco Pharmaceutical
Sun Pharmaceutical Acquires 11.6% Stake In Taro Pharmaceuticals
Sun Pharmaceutical Acquires Controlling Stake In Taro Pharmaceutical
Sun Pharmaceutical Industries Acquires Chattem Chemicals From Elcat
Sun Pharmaceutical Acquires Able Laboratories
Sun Pharmaceutical Industries Acquires Phlox Pharmaceuticals
Sun Pharmaceutical Industries Acquires Additional 1.87% Stake In Caraco Pharmaceutical Laboratories

LIST OF FIGURES

Sun Pharmaceutical Industries Limited – Pipeline by Therapy Area and Indication, H2 2011
Sun Pharmaceutical Industries Limited – Pipeline by Stage of Development, H2 2011
Sun Pharmaceutical Industries Limited – Monotherapy Products in Pipeline, H2 2011
Sun Pharmaceutical Industries Limited – Pipeline By Therapeutic Class, H2 2011
Sun Pharmaceutical Industries Limited - Pipeline By Target, H2 2011
Sun Pharmaceutical Industries Limited – Pipeline By Route of Administration, H2 2011
Sun Pharmaceutical Industries Limited – Pipeline By Molecule Type, H2 2011

Ask Your Question

Sun Pharmaceutical Industries Limited – Product Pipeline Review – H2 2011
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry: